Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Glucagon RTU, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic 0.03% solution, vehicle sterile solution (placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Nearsightedness, Near Sightedness, Near-sightedness
Interventions
SYD-101 0.01%, SYD-101 0.03%, Vehicle
Drug
Lead sponsor
Sydnexis, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Irwindale, California • Pasadena, California • San Diego, California + 35 more
Conditions
Head and Neck Cancer
Interventions
TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Epinephrine in Endotoxemia in Normal Volunteers

NCT00753402
Conditions
Immune System
Interventions
Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Epinephrine
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
oGVHD, Ocular Graft Versus Host Disease
Interventions
d-MAPPS™ Ophthalmic Solution, Matching vehicle control
Biological
Lead sponsor
Regenerative Ocular Immunobiologics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Palm Harbor, Florida • Boston, Massachusetts
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers

NCT01064986
Conditions
Infections
Interventions
Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Lipopolysaccharide, LPS /Epinephrine, Placebo, Hydrocortisone
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Dry Eye Syndromes, Dry Eye
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more
Conditions
Dry Eye
Interventions
Oxervate, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more